October 1 - 4, 2017
Boston Marriott Copley Hotel
Abstract submission deadline: Friday, July 14
Advance registration deadline: Friday, September 8
Sunday, October 1
Monday, October 2
Tuesday, October 3
Wednesday, October 4
Sunday, October 1
Welcome and Opening Keynotes and Special Lecture6:00 p.m.-8:30 p.m.
Principles of response and resistance to immunotherapy
Levi A. Garraway,
Eli Lilly and Company, Indianapolis, Indiana
Engineering T cells to eradicate tumors in the age of synthetic biology Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington
Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for curesJames P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas
Welcome Reception8:00 p.m.-10:00 p.m.Monday, October 2
Breakfast and Networking Roundtables7:00 a.m.-8:15 a.m.Plenary Session 1: Single Cell Imaging of Cancer ImmunologySession Chair: Matthew F. Krummel, University of California San Franciscot, San Francisco, California
8:15 a.m.-9:45 a.m.
Pathology from the molecular scale on up Garry P. Nolan, Stanford University, Stanford, California
Tracking immune cells in sterile injury and how it pertains to cancerPaul Kubes, University of Calgary, Calgary, Canada
Break9:45 a.m.-10:15 a.m.
Plenary Session 2: Synthetic ImmunotherapySession Chair: Darrell J. Irvine, Koch Institute For Integrative Cancer Research at MIT, Cambridge, Massachusetts10:15 a.m.-12:15 p.m.
Enhancing combination immunotherapy and adoptive cell therapy of cancer via lymph node-targeted vaccinesDarrell J. Irvine
Genetic engineering of therapeutic T cells using synthetic nanoparticles Matthias T. Stephan, Fred Hutchinson Cancer Research Center, Seattle, Washington
Plenary Session 3: Neoantigens: The New BiomarkersSession Chair: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts1:30 p.m.-3:15 p.m.RiboSeq and ye shall find: Non-canonical protein translation in cancer immunosurveillanceJonathan W. Yewdell, National Institute of Allergy and Infectious Diseases, Rockville, Maryland Cell Transfer Immunotherapy Targeting Unique Somatic Mutations in Cancer Steven A. Rosenberg, National Cancer Institute, Bethesda, MarylandDeveloping and improving personalized neoantigen-targeting cancer vaccinesCatherine J. Wu
Identification of breast cancer neoantigens exposed by radiation therapy*
Claire Lhuillier, Weill Cornell Medical College, New York, New York
Break3:15 p.m.-3:45 p.m.Plenary Session 4: A Systems Approach to Immuno-OncologySession Chair: Dana Pe’er, Sloan Kettering Institute, New York, New York
3:45 p.m.-5:30 p.m.
Integrative genomics and immune contexture approach to immuno-oncology Jerome Galon, INSERM UMR 1138, Cordeliers Research Center, Paris, France
Spatio-temporal quirks of IFN-γ regulation of immune responses in tumors Gregoire Altan-Bonnet, National Cancer Institute, Bethesda, MarylandAn Atlas of the Tumor Immune Ecosystem
Genetic mechanisms of immune evasion in colorectal cancer* Marios Giannakis, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts Poster Session A / Reception5:30 p.m.-7:30 p.m.
Top of pageTuesday, October 3
Breakfast and Networking Roundtables7:00 a.m.-8:00 a.m.Plenary Session 5: The Inflammatory Tumor Microenvironment Session Chair: Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York 8:00 a.m.-9:45 a.m.
Immune cell atlas of human lung cancer lesions Miriam Merad
Macrophages orchestrate early dissemination and metastasis.Julio A. Aguirre-Ghiso, Icahn School of Medicine at Mount Sinai, New York, New York
Stromal microenvironments in cancer immunologyShannon J. Turley, Genentech, Inc., San Francisco, California
Lymph node colonization promotes systemic tumor metastasis through induction of immune tolerance*
Nathan E. Reticker-Flynn, Stanford University, Stanford, California
Preventing the recurrence of breast cancer at the metastatic niche using resolution-phase macrophages*
Dalit Barkan, University of Haifa, Haifa, Israel
Break9:45 a.m.-10:15 a.m.Plenary Session 6: Engineering Immune Cells to Treat CancerSession Chair: Carl H. June, University of Pennsylvania, Philadelphia, Pennsylvania10:15 a.m.-12:00 p.m.
CAR therapy: beyond the CD19 paradigmMichel Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York
New directions in T cell therapies for cancer Marcela V. Maus, Massachusetts General Hospital, Cancer Center, Boston, Massachusetts
Updates on CAR T CellsCarl H. June
Poster Session B / Lunch12:00 p.m.-2:30 p.m.Plenary Session 7: The Microbiome in Cancer Immunity Session Chair: Giorgio Trinchieri, National Cancer Institute, Bethesda, Maryland2:30 p.m.-4:30 p.m.
Cancer and the microbiome Giorgio Trinchieri
Fusobacterium nucleatum and colon cancer Wendy Garrett, Harvard T.H. Chan School of Public Health, Cambridge, Massachusetts
Understanding response and resistance to cancer therapy: Lessons learned from melanoma Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas
Drugging the human microbiome for combination with tumor immunotherapy* David N. Cook, Seres Therapeutics, Cambridge, Massachusetts
Fusobacterium species, microsatellite instability, and exome-wide neoantigen load in relation to immune response to colorectal cancer* Shuji Ogino, Brigham and Women’s Hospital, Boston, Massachusetts Break4:30 p.m.-4:45 p.m.Plenary Session 8: Metabolic Regulation of Immune ResponsesSession Chair: Luke A. J. O’Neill, Trinity College Dublin, Dublin, Ireland4:45 p.m.-6:30 p.m.
Krebs cycle reprogrammed for cytokinesLuke A. O’Neill
Identification of essential genes for cancer immunotherapyNicholas P. Restifo, National Cancer Institute, Bethesda, Maryland
Immunometabolic circuits in myeloid cell reprogramming Mihai Netea, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
Metabolic adaptations establish immunotherapy resistance in melanoma*
Ashvin R. Jaiswal, The University of Texas MD Anderson Cancer Center, Houston, Texas
Top of page
Wednesday, October 4Continental Breakfast7:00 a.m.-8:00 a.m.Plenary Session 9: New Combination Therapies
Session Chair: Sandra Demaria, Weill Cornell Medical College, New York, New York 8:00 a.m.-9:45 a.m.
Strategies to optimize the adjuvant role of radiotherapy during cancer immunotherapy Silvia C. Formenti, Weill Cornell Medicine, New York, New York
Cancer Immunotherapy: Translational Control of Immune Checkpoint Caroline Robert, Institut de Cancerologie Gustave Roussy, Villejuif, France
Novel insights into the dose-dependency of radiation immunogenicity Sandra Demaria
Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies*
Elizabeth E. Evans, Vaccinex, Rochester, New York
Break9:45 a.m.-10:15 a.m.
Plenary Session 10: Checkpoints and Immunomodulation Session Chair: Joshua D. Brody, Icahn School of Medicine at Mount Sinai, New York, New York10:15 a.m.-11:30 a.m.
Regulatory T Cells and Radiation TherapyCharles G. Drake, Columbia University Medical Center, New York, New York
Improving Checkpoint Blockade for Lymphoma with Flt3L-Primed In Situ Vaccination Joshua D. Brody, Icahn School of Medicine at Mount Sinai, New York, New York
Cancer-germline antigens discriminate clinical outcome to CTLA4 blockade*
Sachet Shukla, Dana-Farber Cancer Institute, Boston, Massachusetts
Closing Remarks and Departure11:30 a.m. a.m.
*Short talk from proffered abstract
Top of page